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Here, we report the diversity of amantadine-resistant mutants among avian influenza A viruses with pandemic potential (H5, H6, H7, and
H9 hemagglutinin subtypes). Drug-resistant variants were not detected among 1979–83 isolates, whereas 31.1% of H5 and 10.6% of H9
strains from Southeast Asia isolated in 2000–04 carried mutations in M2 protein. In North America, resistant variants occurred among H7
viruses only (16.4% of those tested). H6 viruses were amantadine-sensitive. These findings prompt concern regarding the control of
pandemic influenza, the possibility that the next pandemic virus will be amantadine-resistant and the need to monitor the use of the drug in
poultry.
D 2005 Elsevier Inc. All rights reserved.Keywords: Avian influenza A virus; Amantadine resistance; M2 proteinIntroduction
Newly emerging avian influenza A viruses pose a
continued threat, not only to avian species but also to
humans. In 1997, a highly pathogenic H5N1 influenza virus
was isolated from 18 humans, demonstrating direct trans-
mission of avian influenza viruses to humans (Claas et al.,
1998; Suarez et al., 1998). In 1999, two cases of human
infection with avian H9N2 influenza viruses were reported
in Hong Kong (Peiris et al., 1999). More recently, an
outbreak of highly pathogenic avian H7N7 influenza in the
Netherlands in 2003 was associated with conjunctivitis in
349 humans and the death of a veterinarian (Koopmans et
al., 2004), and in February 2004, H7N3 viruses were
reported to infect humans in Canada (Kermode-Scott,
2004). At the same time, between late 2003 and early0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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occurred among poultry in eight Asian countries (Li et al.,
2004), with human cases of H5N1 infection in Vietnam and
Thailand associated with a mortality rate approaching 70%
(WHO, 2004). In addition, recent avian H6N1 viruses were
shown to have internal genes genetically similar to those of
human H5N1 and H9N2 influenza isolates, suggesting that
H6N1 viruses could become novel human pathogens (Chin
et al., 2002). It is worth mentioning that the most recent
H5N1 strains isolated in Southeast Asia were resistant to
amantadine and rimantadine (Li et al., 2004); a group of
antiviral drugs used for treatment and prevention of human
influenza A virus infections. These drugs inhibit virus
replication during the early stage of infection by blocking
the ion channel formed by the M2 protein. Substitution of
one of five amino acids (positions 26, 27, 30, 31, and 34)
within the transmembrane domain of M2 has been imp-
licated in loss of sensitivity to M2 blockers (Hay et al.,
1985; Pinto et al., 1992). However, to our knowledge, there
is no information on the frequency of amantadine-resistant
variants in field isolates of avian influenza A viruses,05) 102 – 106
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subtypes with pandemic potential. In this study, we analyzed
sequence data on matrix (M) genes of avian influenza
viruses of the H5, H6, H7, and H9 HA subtypes that were
isolated in North America and Southeast Asia during 1979–
83 and 2000–04 and evaluated the frequency of drug-
resistant strains.Results and discussion
The analysis was based on the M gene sequences from
60 viruses isolated in Southeast Asia and 74 viruses from
North America and were representative of two time periods
(1979–83 and 2000–04) (Table 1). To systematically
examine the avian gene pool circulating in both geo-
graphical regions, we also included sequence data available
in GenBank on 408 strains from various avian hosts. Our
analysis showed a diversity in the frequency of amantadine-
resistant variants among different HA subtypes, years of
isolation, and geographical areas (Table 1, Fig. 1). Interest-
ingly, analysis of viruses isolated during 1979–83 did not
reveal H5, H7, or H9 isolates with amino acid substitutions
in the transmembrane region of M2 protein corresponding to
resistance to adamantanes (amantadine and rimantadine)
(Table 1). This finding was a feature of North American as
well as Southeast Asian isolates. In contrast, drug-resistant
strains occurred among viruses of all three of these HA
subtypes obtained during 2000–04 (Table 1). Viruses of the
H6 HA subtype were the only exception: analysis of
sequence data obtained from H6 strains isolated from both
regions did not reveal variants with M2 protein-associated
mutations that would confer resistance to amantadine (Table
1, Fig. 1B).
The frequency of emergence of drug-resistant strains
varied among HA subtypes (H5, H7, and H9) during 2000–
04 (Table 1). In the present study, we did not identify M2-
ion channel resistant viruses among the H5 and H9
influenza A viruses circulating in North American region
(Table 1, Figs. 1A, D). However, sequence analysisTable 1
Amantadine-resistant variants among avian influenza A viruses isolated in North
Viruses Year of isolation Hemagglutinin subtypes
H5 H6
North
America
Southeast
Asia
No
Am
From GenBank 1979–83 1 1 0
2000–04 17 114 16
Sequenced in this study 1979–83 10 6 14
2000–04 6 21 (8)a 15
Number of resistant
variants (%)
1979–83 0 0 0
2000–04 0 42 (31.1) 0
Amantadine resistance-associated mutations present in the M2 gene of viruses of th
(17%), and S31N (62%); of the H7 HA subtype were V27A (11%), A30S (22%)
a In parenthesis, the number of drug-resistant variants identified among virusesdetermined 2 resistant H7 variants from northeastern United
States among the 8 avian viruses from this region
characterized in the present study. In total, 9 of the 55
available North American H7 isolates were amantadine-
resistant (Table 1), corresponding to an overall frequency of
about 10% from 2000 to 2004 (Fig. 1C). Previously, it was
shown that 7 of 9 H7 influenza A viruses that were
associated with disease outbreaks in commercial poultry in
the United States had the V27A and S31N amino acid
substitutions in the M2 protein, and the amino acid sequence
of the HA cleavage site of these 7 viruses fulfilled the
molecular criteria for highly pathogenic avian influenza
viruses (Spackman et al., 2003). Our finding is consistent
with the idea that H7 viruses circulating in poultry could
provide an opportunity for random selection of variants with
amino acid changes in M2 transmembrane sequences. The
likelihood of such generation could be high due to
accumulation in the viral genome of random point mutations
caused by the viral transcriptase, a situation that can be
enhanced by rapid spread of the highly pathogenic viruses.
On the other hand, the percentage of H7 drug-resistant
variants (16.4%) could be explained due to the limited
number of available isolates.
The pattern of frequency of resistant strains circulating in
Southeast Asia differed from that in North America.
Sequence analysis of Asian isolates identified 8 H5 and 1
H9 amantadine-resistant influenza variants and included 5
viruses isolated from chickens, 3 viruses isolated from silky
chickens, and 1 virus isolated from a pheasant (Tables 1 and
2). Importantly, the largest proportion of Asian drug-
resistant avian viruses of H5 and H9 subtypes occurred in
China. In contrast, avian H7 influenza viruses from Asia
were sensitive to M2 inhibitors (Table 1, Fig. 1C). Taking
into account that H9N2 viruses were the most prevalent HA
subtype in the live-poultry markets in southeastern China
between 2001 and 2004 and that these viruses exhibited
increasing genetic and biologic diversity (Choi et al., 2004),
our identification of a frequency of 10.6% for amantadine
resistance among H9 strains might be explained by the
diverse nature of the gene pool. Further, the percentage ofAmerica and Southeast Asia
H7 H9
rth
erica
Southeast
Asia
North
America
Southeast
Asia
North
America
Southeast
Asia
0 0 0 1 2
7 47 0 0 35
6 6 2 4 3
10 8 (2) 0 11 12 (1)
0 0 0 0 0
0 9 (16.4) 0 0 5 (10.6)
e H5 HA subtype were at positions V27A (21% of resistant variants), A30S
, and S31N (67%); and of the H9 HA subtype was S31N (100%).
sequenced in the present study.
Fig. 1. Appearance of amantadine-resistant variants among avian influenza viruses of H5, H6, H7, and H9 HA subtypes between 1991 and 2004. Sequence
analysis (GenBank) revealed 1 drug-resistant variant of the H5, 2 of the H6, 1 of the H7, and 3 of the H9 HA subtypes among viruses isolated during 1991–99.
Amantadine-resistant variants isolated in 2000–04 are presented in Table 1.
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contrast to the number of resistant variants among H6, H7,
and H9 HA subtypes (Table 1). One of the possible
explanations that we were not able to identify any drug-
resistant H6 and H7 viruses in Asia could be due to the
limited number of available isolates. The distribution of the
mutations in the M2 genes of H5 HA suggests that they
were independently acquired rather than having descended
from a single lineage of amantadine-resistant M2 genes. InTable 2
Amantadine sensitivity assay of influenza viruses in MDCK cells
Virus Subtype
A/Duck/Jiangxi/6151/2003 H5N3
A/Chicken/Pennsylvania/143586/2002 H7N2
A/Chicken/Hong Kong/WF208/2001 H9N2
A/Chicken/Hong Kong/SF131/2003 H5N1
A/Chicken/Hong Kong/SSP94/2003 H5N1
A/Silky Chicken/Hong Kong/YU238/2003 H5N1
A/Chicken/Hong Kong/YU250/2003 H5N1
A/Silky Chicken/Hong Kong/YU316/2003 H5N1
A/Silky Chicken/Hong Kong/SSP7/2003 H5N1
A/Chicken/Hong Kong/SSP139/2003 H5N1
A/Pheasant/Hong Kong/NT23/2003 H5N1
A/Chicken/CT/9407/2003 H7N2
A/Chicken/NY/116124/2003 H7N2
A/Chicken/Hong Kong/FY313/2000 H9N2
a Susceptibility to amantadine was determined by plaque reduction assay in M
standard deviation (SD).
b No mutations that confer resistance to amantadine.addition, the rate of mutation in the M2 gene was expected
not to be quiet high among all HA subtypes: about 11 
103 substitutions per nucleotide site per year (Rodgers and
Swofford, 1998). Therefore, there is no direct evidence, but
in light of the genetic stability of this particular gene
segment (Trampuz et al., 2004), we speculate that H5 avian
viruses with amino acid residues in the M2 protein, that
confer resistance to the amantadine, have a selective
advantage in poultry in Asia and would not occur naturally.M2 mutation that confers
resistance to amantadine
IC50
(mean T SD, AM)a
–b 0.10 T 0.02
– 0.10 T 0.04
– 0.49 T 0.07
V27A 100
V27A 100
V27A 100
S31N 100
V27A 100
S31N 100
V27A 100
V27A 100
A30S 33.2 T 2.6
A30S 44.1 T 3.7
S31N 100
DCK cells. Results are the mean values (IC50, AM) of two experiments T
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overall frequency of resistant H5 strains was 33.8% during
2000–04 (Fig. 1A) and that ¨30% to 80% of patients
usually shed resistant strains when amantadine or rimanta-
dine is used for therapy of influenza virus infections among
untreated adults (Saito et al., 2003).
In the present study, we identified 11 drug-resistant
variants of H5, H7, and H9 HA subtypes among all 134
viruses sequenced. These strains possessed amino acid
substitutions in the M2 protein at three positions – V27A,
A30S, and S31N (Table 2) – reported previously to confer
resistance to amantadine (Hay et al., 1985; Pinto et al.,
1992). Among the characterized resistant viruses, 62% of
the H5, 67% of the H7, and 100% of the H9 strains
demonstrated the S31N substitution (Table 1). We verified
the susceptibility to amantadine of all 11 strains by plaque
reduction assay in MDCK cells, using as controls repre-
sentatives of each subtype that lacked the M2 changes
associated with resistance to amantadine. IC50 values for H7
mutants were ¨350-fold higher than those for H7 drug-
sensitive virus (Table 2). Amantadine concentrations as high
as 100 AM failed to inhibit replication of H5 and H9 drug-
resistant viruses. In contrast, A/Duck/Jiangxi/6151/2003
(H5N3) virus could be inhibited almost completely by
amantadine at concentration as low as 0.1 AM. With A/
Chicken/Hong Kong/WF208/2001 (H9N2) virus, a 50%
reduction was seen with a drug concentration of 0.49 AM
(Table 2). It was reported, that the mutations that confer
amantadine resistance are located in the transmembrane
domain of the M2 protein at one of five amino acid
positions: 26, 27, 30, 31, and 34. These residues differ in
their effects on binding of amantadine: viruses with S31N or
A30T(S) amino acid substitutions no longer bind the
blocker, which therefore can no longer exert its inhibitory
function, whereas viruses with mutations at residue 26 or 27
retain binding of the blocker, but function of the M2 protein
is not inhibited (Astrahan et al., 2004). In our study we
confirmed that H5, H7, and H9 avian influenza A viruses
with V27A, A30S, or S31N amino acid substitutions in their
M genes exhibited high-level resistance to amantadine, with
100-fold reduction in susceptibility compared with that of
sensitive viruses of similar HA subtype (Table 2).
In this study, M gene sequence analysis of viruses
distributed among four HA subtypes revealed that the
percentage of drug-resistant avian H7 and H9 viruses
between 2000 and 2004 was ¨10–15% and that the
appearance of H6 amantadine-resistant mutants was a rare
event (Figs. 1B, C, D). This finding can be explained by the
idea that under the described epidemiological conditions,
such mutants may appear. The high frequency of H5
amantadine-resistant influenza viruses and its tendency to
increase in recent years is in sharp contrast to the levels of
resistance among other HA subtypes (Fig. 1). Furthermore,
the M gene phylogenetic tree revealed that there was no
clear separation of H5 amantadine-resistant variants into a
particular distinct lineage; conversely, they belonged tomultiple sublineages of Eurasian avian-like lineage (the M
gene phylogenetic trees of H5, H7, and H9 viruses that
include the drug-resistant variants are available online at
http://www.stjuderesearch.org/data/amantadine/). This ob-
servation prompts concern not only about the possibility
that a putative pandemic strain will be resistant to
amantadine, but also about the fact that it might not occur
randomly because of the limited mutation rate per nucleo-
tide per year. Although the high replication efficiency of
highly pathogenic viruses may favor the emergence of
mutations, but the resistant variants do not appear to be
more virulent, genetically stable, or capable of competing
with wild, drug-sensitive strains (Bean et al., 1989; Saito et
al., 2003). Therefore, the primary emerged drug-resistant
mutants have no survival advantages. Furthermore, high
accumulation of random mutations likely would not take
place because of the high mortality rate among infected
hosts and rapid spread of the highly pathogenic viruses. The
single worrisome alternative regarding selection of resistant
strains is that the poultry farmers in Asia are adding
amantadine to chicken food to protect birds during H5
influenza virus outbreaks in domestic birds. Our findings
that H6 viruses had no resistance-related mutations might be
explained by the fact that H6 viruses cause unapparent
infections of domestic chickens and thus there would be no
need to treat the poultry with amantadine.
This study is the first attempt to evaluate the frequency of
amantadine-resistant variants among potentially pandemic
avian influenza viruses circulating in North America and
Southeast Asia. Our findings highlight the necessity of
monitoring the susceptibility of avian strains to antiviral
drugs and, moreover, the urgent need to control the use of
these drugs during outbreaks of highly pathogenic influenza
viruses in poultry.Materials and methods
Virus isolates
We characterized 134 avian influenza viruses representa-
tive of H5, H6, H7, and H9 HA subtypes that we obtained
from the St. Jude Children’s Research Hospital repository (a
list of the influenza viruses characterized in this study is
available on request). The viruses were grown in the
allantoic cavity of 10-day-old embryonated chicken eggs.
RNA isolation, PCR amplification, and sequencing
Viral RNA was isolated from virus-containing allantoic
fluid by using the RNeasy Mini kit (Qiagen, Valencia, CA)
according to the manufacturer’s protocol. Reverse tran-
scription of viral RNA and subsequent PCR was performed
using primers specific for the M gene segment, as described
previously (Hoffmann et al., 2001). PCR products were
purified with QIAquick PCR purification kit (Qiagen)
N.A. Ilyushina et al. / Virology 341 (2005) 102–106106according to the manufacturer’s protocol. The sequencing
reaction was performed by the Hartwell Center for
Bioinformatics and Biotechnology at St. Jude Children’s
Research Hospital. The DNA template was sequenced by
using rhodamine or dRhodamine dye terminator cycle-
sequencing Ready Reaction kits with AmpliTaqDNA
polymerase FS (Perkin-Elmer, Applied Biosystems, Inc.,
Foster City, CA) and synthetic oligonucleotides. Samples
were analyzed in a Perkin-Elmer Applied Biosystems model
373 or model 377 DNA sequencer. DNA sequences were
completed and edited by using the Lasergene sequence
analysis software package (DNASTAR, Madison, WI).
Nucleotide sequences obtained in this study have been
deposited in the GenBank database under accession num-
bers DQ107406–DQ107518.
Susceptibility to amantadine
Amantadine sensitivity was determined by plaque
reduction assay on Madin–Darby canine kidney cells
(MDCK, ATCC, Manassas, VA), as described previously
(Hayden et al., 1980). Six-well plates were inoculated with
virus diluted in minimal essential medium (MEM) to give
80 to 100 plaques per well. Cells were incubated for 1 h at
37 -C and then overlaid with MEM containing 0.9% agar,
4% bovine serum albumin, 1Ag/ml l-1-(tosylamido-2-
phenyl)ethyl chloromethyl ketone (TPCK)-treated trypsin
(Worthington Diagnostics, Freehold, NJ), and amantadine
(1-aminoadamantane hydrochloride, Sigma-Aldrich, Inc.,
St. Louis, MO) at different concentrations (0.01 to 100
AM). After 3 days of incubation at 37 -C, plaques were
visualized by staining with 0.1% crystal violet containing
10% formaldehyde. The percentage inhibition of plaque
formation relative to untreated controls was calculated for
each drug concentration. Two independent experiments
were performed to determine the drug concentration
resulting in a 50 % reduction of the plaque number (IC50).
Three amantadine-sensitive viruses of the H5, H7, and H9
subtypes [A/Duck/Jiangxi/6151/2003 (H5N3), A/Chicken/
Pennsylvania/143586/2002 (H7N2), and A/Chicken/Hong
Kong/WF208/2001 (H9N2)] were used to compare the
susceptibility of amantadine-resistant strains with that of
those that lacked changes in M2 protein.Acknowledgments
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